Small-Molecule Injectable Market

2016-2020 Small Molecule Injectable Market Demand Outlook Compared to 2021-2031 Forecast

Sales of small molecule injectable grew at a CAGR of 4.8% between 2016 and 2020. Growing prevalence of chronic diseases and fast track approvals of new drugs for treatment are expected to drive sales of small molecule injectables.

Leading pharmaceutical companies are aiming at production facility expansion through mergers acquisitions and collaborations to improve their product portfolios. For Instance, In April 2021, Dr. Reddy's Laboratories announced the launch of a generic version of Sapropterin Dihydrochloride powder for oral solution, 100 mg in the U.S. Market.

In July, 2020, USFDA cGMP inspection completed at Cipla's API manufacturing facility in Virgonagar, Bengaluru. These developments are expected to bode well for the global small-molecule injectables market.

Considering this, FMI expects the global small molecule injectable to grow at a CAGR of 7.3% through 2031.

Download a Comprehensive Report Snapshot

Which Factors Are Restraining Demand for Small Molecule Injectable?

Small-molecule injectables require complex equipment for manufacturing, each of which need proper certification and sterilization before production. This leads to high operating costs and high debt levels too due to purchase and renting of capital equipment.

In addition to this, regulatory cost burden is high due to FDA mandates for maintaining quality of product while manufacturing,packaging, storage and distribution.

Monopoly in manufacturing and sourcing of small-molecule injectables is also causing disruptions in supply chain. This might hamper the availability of drugs, resulting in dampened sales prospects for small-molecule injectables.

What is the Impact of the COVID-19 Crisis on the Small-Molecule Injectable Market?

The COVID-19 pandemic is anticipated to have a negative impact on the small molecule injectable market due to limited production and  transportation-related delays. Lockdown restrictions further made it difficult for freight service providers to deliver raw material.

However, resumption in production activities and across various sectors is expected to augment recovery of the small-molecule injectables market in the forthcoming years. Manufacturers and healthcare professionals are also amplifying their efforts to spread awareness regarding immunotherapy treatment options. This is expected to propel sales of small-molecule injectables over the forecast period.

Country-wise Insights

Will the U.S. Remain a Key Small-Molecule Injectable Market?

The U.S. is estimated to account for over 92.4 % of the North America small-molecule injectable market in 2021. Demand for small-molecule injectables is increasing in the U.S due to increasing incidence of chronic diseases among the geriatric population, and growing rates of hospitalisation and surgeries.

Why is Germany Considered a Lucrative Small-Molecule Injectable Market?

Germany is expected to account for 21.9% of the Europe small-molecule injectable market in Europe by 2031. Growing demand for small-molecule injectables in Germany is attributable to rapid expansion of healthcare infrastructure, presence of prominent players and rapid adoption of technologically advanced equipment and processes in the healthcare sector.

What are the Factors Fueling Small-Molecule Injectable Sales in China?

Sales of small-molecule injectables in China are projected to grow at a 9.0% CAGR in East Asia throughout the forecast period. Increasing use of oncology-related medicines in hospitals for treatment of various types of cancer, rising demand for analgesics for surgical pain management and wide avaiblity of biopharmaceutical raw material are expected to continue pushing sales of small-molecule injectables in China.

How will the Small-Molecule Injectable Market Expand Across India?

Demand for small-molecule injectables in India is expected to rise at an impressive 11.1% CAGR over the forecast period.  Rising health care awareness, surging demand for advanced medical technologies, increasing number of hospitalization, and streamlined raw material procurement are expected to drive expansion of the small-molecule injectable market in India.

Category-wise Insights

Demand for Analgesics to Continue gaining Traction

By product, the analgesics segment is anticipated to hold the maximum share of 23.9% in 2021, expanding at 8.0% CAGR during the forecast period. Revenues from analgesics are expected to expand further, primarily due to increasing number of accidents, surgeries and hospitalizations. Analgesics help in pain management, relieve anxiety, improve healing and accelerate recovery.

Applications of Small-Molecule Injectables in Infectious Diseases to Remain High

In terms of application, the infectious disease sement in projected to account for 31.7% of the total market share in 2021.  Increasing adoption of small-molecules injectable drug in infectious disease control and treatment is expected to continue spurring demand for small-molecule injectables during the forecast period.            

Which Route of Administration will be Most Preferred?

By route of administration, the intravenous segment is projected to account  for 49.8% of the total market share in 2021. Intravenous route is considered to be the fastest route of drug administration and injectable are directly introduced into the bloodstream. Considering this, sales of small-molecule injectables in the intravenous route of administration segement are expected to remain high over the forecast period.

Sales of Small-Molecule Injectables through Hospital Pharmacies to Remain High

By distribution channel, hospital pharmacies are anticipated to account for 67.8% of the total small-molecule injectable market share in 2021.  Increasing hospitalizations, and the availability of skilled professionals to inject drugs is likely to fuel growth of the segment.

Competitive Landscape

Companies operating in the small molecule Injectable are investing in strategic collaborations, mergers and acquisitions to improve their product portfolios. Drug approvals and production facility expansions will remain a part pf growth strategies adopted by market players to gain a competitive edge. For instance:

• In March 2021, U.S. Food and Drug Administration (FDA) has accepted new drug application for gefapixant, an intravenous administered for the treatment of refractory chronic cough (RCC) in adults.
• In 2021, Novartis announced that small drug molecule (branaplam) is in Phase 2 for spinal muscular atrophy.
• In Jan 2020, Sanofi S.A acquired Syntrox for biotechnological product development for cancer and autoimmune disorders.

Scope of the Report

Key Questions Answered in Report

• What is the current value of the global small-molecule injectable market?

  The global small-molecule injectable market is projected to expand at a 7.3% CAGR over the forecast period.

• At what rate did the market grow between 2016 and 2020?

  The global small-molecule injectable market expanded at a 4.8% CAGR between 2016 and 2020.

• What are key trends driving sales of small-molecule injectables?

  Increasing adoption of automation in drug production, focus on manufacturing quality, product launch, rising government initiatives and growing market consolidation activities by manufacturer are key trends driving sales of small molecule injectable across the globe.

• What are the key market statistics of South Korea and Japan?

  The South Korea small molecule injectable market is projected to expand at a 5.0% CAGR during the forecast period. Sales of small-molecule injectables in Japan are slated to grow at a 8.8% CAGR during the forecast period.

• What are the top 5 countries driving demand for small molecule injectable market?

  The U.S., China, India, Germany, and Japan are top 5 countries that are driving demand for small molecule injectable market

• Which are leading companies of small molecule injectable market?

  Leading companies of small molecule injectable are Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A S.A., Sun Pharmaceutical Industries Ltd., AstraZeneca Plc, Merck & Co., Inc., Mylan N.V, Cipla Inc., and Dr. Reddy’s Laboratories Ltd.

Small Molecule Injectable Market by Category

By Product:

• Small Molecule Antibiotics  
• Chemotherapy Agents
• Local and General Anaesthetics
• Skeletal Muscle Relaxants
• Analgesics
• Anticoagulants
• Anticonvulsants
• Antivirals
• Anti-histamines/ Anti-allergy
• Others

By Application:

• Oncology
• Pain Management
• Cardiovascular Diseases
• Infectious Diseases
• CNS Diseases
• Blood Disorders
• Musculoskeletal Disorders
• Others

By Route of Administration:

• Intravenous (IV)
• Intramuscular (IM)
• Subcutaneous (SC)

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Mail Order Pharmacies

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)